• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Halozyme Therapeutics Inc.

    10/17/24 9:36:19 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HALO alert in real time by email
    SC 13G 1 Halozyme_Thera_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    HALOZYME THERAPEUTICS INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    40637H109

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    40637H109 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    6,127,963

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    6,635,827

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,635,827.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.2%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    40637H109 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      HALOZYME THERAPEUTICS INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      12390 EL CAMINO REAL SAN DIEGO CA 92130 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      40637H109

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    40637H109 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 6,635,827.00  
      (b) Percent of class: 5.2%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 6,127,963
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 6,635,827
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ¨
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET BANK AND TRUST COMPANY (BK) STATE STREET GLOBAL ADVISORS (JAPAN) CO., LTD. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    40637H109 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $HALO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HALO

    DatePrice TargetRatingAnalyst
    12/4/2025$56.00Neutral → Sell
    Goldman
    10/14/2025$70.00Underperform → Market Perform
    Leerink Partners
    8/6/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    7/10/2025$55.00Neutral
    Goldman
    5/14/2025$62.00Overweight → Equal-Weight
    Morgan Stanley
    5/13/2025$47.00Market Perform → Underperform
    Leerink Partners
    10/7/2024$58.00 → $62.00Overweight → Equal Weight
    Wells Fargo
    9/19/2024$52.00 → $57.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $HALO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

    Announcing New $1 billion Share Repurchase ProgramProjecting to Buy Back at Least $400 million in 2026Total Revenue Increased 42% YOY to $377 millionRoyalty Revenue Increased 43% YOY to $241 millionReiterating 2026 Financial Guidance Ranges:Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30%Royalty Revenue of $1.130 - $1.170 billion, YOY Growth of 30% - 35%Adjusted EBITDA of $1.125 - $1.205 billion, YOY Growth of 71% - 83%1Non-GAAP Diluted EPS of $7.75 - $8.25, YOY Growth of 87% - 99%1SAN DIEGO, May 11, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March

    5/11/26 4:01:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

    Marks first ENHANZE® agreement to include ADC targetsCollaboration also includes option for additional future targetsFirst clinical trial projected to initiate in 2026SAN DIEGO, May 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced the Company entered into a global collaboration and license agreement with GSK. Under the collaboration, GSK has licensed Halozyme's ENHANZE® drug delivery technology for the development and potential commercialization of subcutaneous administration of multiple oncology targets, including antibody drug conjugates (ADCs), as well as an option for additional future drug targets."We are excited to work wit

    5/7/26 9:00:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

    Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional targetSAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") and Oruka Therapeutics, Inc. (NASDAQ:ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.Under the agreement, Oruka has licensed Halozyme's Hypercon™ technology for use with ORKA‑001, in development for psoriasis and related inflammatory diseases, and up to one additional target. Hypercon™ is an innovative microparticle technology that allows for

    5/6/26 8:00:00 AM ET
    $HALO
    $ORKA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $HALO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Torley Helen sold $3,370,008 worth of shares (50,000 units at $67.40) as part of a pre-agreed trading plan and exercised 50,000 shares at a strike of $12.07 (SEC Form 4)

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    6/3/26 8:06:58 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Connaughton Bernadette sold $107,591 worth of shares (1,625 units at $66.21) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 43,669 units (SEC Form 4)

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    6/2/26 5:20:34 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT AND CEO Torley Helen exercised 50,000 shares at a strike of $12.07 and sold $3,433,875 worth of shares (50,000 units at $68.68) as part of a pre-agreed trading plan (SEC Form 4)

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    5/13/26 5:50:19 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Halozyme Therapeutics downgraded by Goldman with a new price target

    Goldman downgraded Halozyme Therapeutics from Neutral to Sell and set a new price target of $56.00

    12/4/25 8:27:01 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Halozyme Therapeutics from Underperform to Market Perform and set a new price target of $70.00

    10/14/25 1:19:46 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Halozyme Therapeutics from Equal-Weight to Overweight and set a new price target of $75.00

    8/6/25 7:53:02 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    SEC Filings

    View All

    SEC Form 10-Q filed by Halozyme Therapeutics Inc.

    10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    5/11/26 4:09:29 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    5/11/26 4:06:06 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    5/7/26 4:16:24 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Leadership Updates

    Live Leadership Updates

    View All

    Halozyme Appoints Darren Snellgrove as Chief Financial Officer

    SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026.Mr. Snellgrove will be responsible for leading Halozyme's financial operations and strategy, including capital allocation, corporate development and investor relations. Darren will report to Helen Torley, President and Chief Executive Officer."I am delighted to have a financial leader of Darren's experience and caliber join Halozyme at this exciting time. He is a highly respected finance leader with deep experience and an expansive skillset, demonstrated by successful leadershi

    4/30/26 8:00:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Appoints David Ramsay as Interim Chief Financial Officer

    SAN DIEGO, March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer (CFO), effective March 23, 2026. Mr. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO.Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale‑up. He previously served as Halozyme's Chief Financial Officer from 2003 to 2009 and again from 2013 to 2015, during w

    3/12/26 8:30:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jim Lang Elected to Halozyme's Board of Directors

    SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics. "Jim brings extensive experience in building and scaling innovative healthcare businesses, and we are delighted to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His strategic insight and proven ability to drive growth, including through M&A, will be a tremendous asset as we deliver on our growth strategy and create meaningful new value for our

    12/8/25 4:05:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Financials

    Live finance-specific insights

    View All

    HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

    Announcing New $1 billion Share Repurchase ProgramProjecting to Buy Back at Least $400 million in 2026Total Revenue Increased 42% YOY to $377 millionRoyalty Revenue Increased 43% YOY to $241 millionReiterating 2026 Financial Guidance Ranges:Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30%Royalty Revenue of $1.130 - $1.170 billion, YOY Growth of 30% - 35%Adjusted EBITDA of $1.125 - $1.205 billion, YOY Growth of 71% - 83%1Non-GAAP Diluted EPS of $7.75 - $8.25, YOY Growth of 87% - 99%1SAN DIEGO, May 11, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March

    5/11/26 4:01:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme to Report First Quarter 2026 Financial and Operating Results

    SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating results on Monday, May 11, 2026, following the close of trading.Halozyme will host a conference call on Monday, May 11, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/178516398?pwd=q41k1S5tA live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.About HalozymeHalozyme is a biopharmaceutical company advancing

    4/30/26 4:30:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

    Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 millionCompleted Acquisitions of Elektrofi's Hypercon™ Technology and Surf Bio's Hyperconcentration TechnologyReiterating 2026 Financial Guidance Ranges:Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30%Adjusted EBITDA of $1.125 - $1.205 billion, YOY Growth of 71% - 83%1Non-GAAP Diluted EPS of $7.75 - $8.25, YOY Growth of 87% - 99%1SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 

    2/17/26 4:01:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Halozyme Therapeutics Inc.

    SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    11/12/24 9:36:57 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Halozyme Therapeutics Inc.

    SC 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    10/17/24 9:36:19 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)

    SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    2/13/24 5:06:13 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care